|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2010-12-14
|
|
pubmed:abstractText |
Dendritic cell-derived exosomes (Dex) are nanovesicles bearing major histocompatibility complexes promoting T-cell-dependent antitumor effects in mice. Two phase I clinical trials aimed at vaccinating cancer patients with peptide-pulsed Dex have shown the feasibility and safety of inoculating clinical-grade Dex, but have failed to show their immunizing capacity. These low immunogenic capacities have led us to develop second-generation Dex with enhanced immunostimulatory properties. Here, we show that interferon-? is a key cytokine conditioning the dendritic cell to induce the expression of CD40, CD80, CD86, and CD54 on Dex, endowing them with direct and potent peptide-dependent CD8(+) T-cell-triggering potential in vitro and in vivo. In this study, we describe the clinical grade process to manufacture large-scale interferon-?-Dex vaccines and their quality control parameters currently used in a phase II trial.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, CD40,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, CD80,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, CD86,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, Neoplasm,
http://linkedlifedata.com/resource/pubmed/chemical/Cancer Vaccines,
http://linkedlifedata.com/resource/pubmed/chemical/Intercellular Adhesion Molecule-1,
http://linkedlifedata.com/resource/pubmed/chemical/Interferon-gamma
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
1537-4513
|
|
pubmed:author |
pubmed-author:ChaputNathalieN,
pubmed-author:CommerePierre-HenriPH,
pubmed-author:GorrichonKevinK,
pubmed-author:LantzOlivierO,
pubmed-author:LapierreValérieV,
pubmed-author:PloixStéphanieS,
pubmed-author:ThéryClotildeC,
pubmed-author:TramalloniDominiqueD,
pubmed-author:TurszThomasT,
pubmed-author:ViaudSophieS,
pubmed-author:Virault-RocroyPaulineP,
pubmed-author:ZitvogelLaurenceL
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
34
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
65-75
|
|
pubmed:meshHeading |
pubmed-meshheading:21150714-Animals,
pubmed-meshheading:21150714-Antigen Presentation,
pubmed-meshheading:21150714-Antigens, CD40,
pubmed-meshheading:21150714-Antigens, CD80,
pubmed-meshheading:21150714-Antigens, CD86,
pubmed-meshheading:21150714-Antigens, Neoplasm,
pubmed-meshheading:21150714-CD8-Positive T-Lymphocytes,
pubmed-meshheading:21150714-Cancer Vaccines,
pubmed-meshheading:21150714-Dendritic Cells,
pubmed-meshheading:21150714-Exosomes,
pubmed-meshheading:21150714-Gene Expression,
pubmed-meshheading:21150714-Humans,
pubmed-meshheading:21150714-Immunoblotting,
pubmed-meshheading:21150714-Intercellular Adhesion Molecule-1,
pubmed-meshheading:21150714-Interferon-gamma,
pubmed-meshheading:21150714-Lymphocyte Activation,
pubmed-meshheading:21150714-Mice,
pubmed-meshheading:21150714-Mice, Transgenic
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
Updated technology to produce highly immunogenic dendritic cell-derived exosomes of clinical grade: a critical role of interferon-?.
|
|
pubmed:affiliation |
Institut National de la Santé et de la Recherche Médicale (INSERM), U1015, Paris, France.
|
|
pubmed:publicationType |
Journal Article
|
